deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT04106856

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Borderline Resectable Pancreatic Adenocarcinoma Locally Advanced Pancreatic Ductal Adenocarcinoma Locally Advanced Unresectable Pancreatic Adenocarcinoma Stage II Pancreatic Cancer AJCC v8 Stage IIA Pancreatic Cancer AJCC v8 Stage IIB Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8
Interventions Hypofractionated Radiation Therapy Losartan Losartan Potassium Quality-of-Life Assessment Questionnaire Administration
Updated 17 times since 2019 Last updated: Apr 3, 2025 Started: Aug 8, 2019 Primary completion: Dec 6, 2024 Completion: Aug 8, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Ductal Adenocarcinoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – present · 15 months · monthly snapshot

Change History

17 versions recorded

  1. May 2025 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — May 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  5. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Aug 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  3. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  4. Jun 2022 — Jun 2023 [monthly]

    Recruiting PHASE1

  5. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  6. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  8. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  9. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  10. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  11. Nov 2019 — May 2020 [monthly]

    Recruiting PHASE1

  12. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Utah
Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations